Cat. No.: DAB-0012159
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IHC |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro240 of human IGFBP1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | IGFBP1 |
| UniProt No. | P08833 |
| Gene ID | 3484 |
| Gene Description | Insulin-like growth factor-binding proteins play an integral role in modifying insulin-like growth factor actions in a wide variety of cell types. There are six known IGFBP family members, which are structurally related, but encoded by distinct genes. IGFBPs have high affinity for IGFs; in some contexts, IGFBPs inhibit IGF actions by preventing access to IGF receptors, while in others they potentiate IGF actions by facilitating ligand-receptor interaction. IGFBP1 is produced primarily by the liver and secreted into circulation, and studies show its expression can be negatively regulated by insulin. Notably, low levels of IGFBP1 were shown to predict the future onset of Type 2 diabetes. Reduced expression of IGFBP1 expression was also associated with tumor progression in breast cancer, prostate cancer, pancreatic cancer and colorectal cancer, possibly stemming from reduced inhibition of mitogenic IGF signaling. Notably however, other research studies have reported increased levels of IGFBP1 in selected tumor types; in human schwannoma, increased IGFBP1 was associated with stimulation of the integrin β1/FAK pathway, supporting the concept of IGF-independent signaling functions for selected IGFBPs. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
